Brian Costell, MD

Brian Costell, MD, is a Boca Raton Neurologist and Epileptologist. Dr. Costell has championed a comprehensive approach to patient care and overall patient well-being. By bringing Neurology, Neuropsychology, Infusion Therapies, and Clinical Research under one roof in Boca Raton, Florida, Dr. Brian Costell has established the continuum of care, resulting in a more efficient and more effective patient experience.

Schedule Appointment(opens in new tab)

Research & Clinical Trials
2012-Present

Amgen ABP-+692 20230309 - A randomized double blind parallel group study to compare pharmacokinetics, pharmacodynamics, clinical effects, and safety between ABP 692 and Ocrevus (Ocrelizumab) in subjects with relapsing-remitting multiple sclerosis (Sub-Investigator)

MapLight ML-007C-MA-221 - A randomized, double blind, placebo-controlled study to assess the efficacy and safety of ML-007C-MA for the treatment of Hallucinations and delusions associated with Alzheimer’s disease psychosis

AbbVie M23-714- Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of Ubrogepant for the treatment of Menstrual Migraine with an open-label extension.

Novartis CLNP-23Q12301- A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of Iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open-label extension phase.

Sanofi EFC17919 – Master protocol of two independent randomized double blind phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis (Sub-Investigator)

Sanofi EFC17504 – A randomized double blind phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with non-relapsing secondary progressive multiple sclerosis (Sub-Investigator)

Argenx ARGX-113-2315 – A randomized double blind placebo controlled phase 3 parallel group design study evaluating the efficacy and safety of Efgartigimod PH20 SC administered by prefilled syringe in adult participants with Ocular Myasthenia Gravis

Biogen 221AD305- A phase 3b/4 randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of Aducanumab (BIIB037) in participants with Alzheimer's Disease.

American College of Radiology ALZ-NET- Alzheimer’s network treatment and diagnostics (ALZ-NET).

Argenx ARGX-113-2308 - A randomized double blind placebo controlled phase 2 parallel group design study evaluating the efficacy and safety of Efgartigimod IV in adult participants with Acetylcholine receptor binding antibody seronegative generalized myasthenia gravis

Cassava PTI-125-10- An open-label, long-term extension study to evaluate the safety and tolerability of Simufilam 100mg tablets in participants with mild to moderate Alzheimer’s disease.

Biohaven BHV3500-302- A phase 2/3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Zavegepant in migraine prevention

AbbVie M22-418- Chronic Migraine: A phase 3 multicenter 24-week open-label study to evaluate the safety, tolerability, and efficacy of Atogepant when added to OnabotulinumtoxinA (BOTOX) for the prevention or treatment of chronic migraine

Eli Lilly I9X-MC-MTAE- Assessment of safety, tolerability, and efficacy of LY3372689 in early symptomatic Alzheimer's Disease

Biohaven BHV3000-404- A phase 4 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety or Rimegepant in episodic migraine prevention with multiple dosing regimens

AbbVie M21-307- Episodic Migraine: Phase 3 study of BOTOX (Botulinum Toxin Type A) for the prevention of migraine in subjects with episodic migraine

Cassava PTI-125-07- A phase 3, randomized, double-blind, placebo-controlled, parallel-group, 52-week study evaluating the safety and efficacy of Simufilam 100mg tablets in subjects with mild-to-moderate Alzheimer's Disease

Eli Lilly I5T-MC-AACM- A study of donanemab versus placebo in participants at risk for cognitive and functional decline al Alzheimer's Disease

Eli Lilly I5T-MC-AACI- Assessment of safety, tolerability, and efficacy of Donanemab in early symptomatic Alzheimer's Disease.

Argenx ARGX-113-2002- A long-term, single-arm, open-label, multicenter, phase 3 study to evaluate the safety and tolerability of multiple subcutaneous injections of Efgartigimod PH20 SC in patients with Generalized Myasthenia Gravis

Argenx ARGX-113-2001- A phase 3, randomized, open-label, parallel-group study to compare the pharmacodynamics, pharmacokinetics, efficacy, safety, tolerability, and immunogenicity of multiple subcutaneous injections of Efgartigimod PH20 SC with multiple intravenous infusions of Efgartigimod in patients with Generalized Myasthenia Gravis

Satsuma STS101-007- A randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of STS101 (Dihydroergotamine Nasal Powder) in the acute treatment of Migraine

Novartis CBAF312AUS02- Exploring the safety and tolerability of conversion from oral or injectable disease-modifying therapies to dose-titrated oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: a 6-month open-label, multi-center Phase IIIb study (EXCHANGE)

EMD Serono/Merck MS200527_0800- A phase III, multicenter, randomized, parallel group, double blind, double-dummy, active-controlled study of Evobrutinib compared with Teriflunomide, in participants with relapsing multiple sclerosis to evaluate efficacy and safety.

Celgene RPC-1063-MS-001- A multicenter, longitudinal, open-label, single-arm study describing cognitive processing speed changes in relapsing multiple sclerosis subjects treated with Ozanimod (RPC-1063)

Eli Lilly I5Q-MC-B004- Preventive treatment of migraine: outcomes for patients in real-world healthcare systems (TRIUMPH)

Allergan 3101-309-002- A phase 3, multicenter, open-label 40-week extension study to evaluate the long-term safety and tolerability of oral Atogepant for the prevention of Migraine in participants with Episodic Migraine

Allergan 3101-301-002- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Episodic Migraine (ADVANCE)

Grunenthal KF7013-02- Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Efficacy And Safety Of Intravenous Neridronic Acid In Subjects With Complex Regional Pain Syndrome (CRPS)

Acadia ACP-NIS-001- Management Of Parkinson's Disease Psychosis In Actual Practice (The INSYTE Study)

Lundbeck NOH402- A Clinical Study Of Patients With Symptomatic Neurogenic Orthostatic Hypotension To Assess Sustained Effects Of Droxidopa Therapy

Genzyme OBS13434-A Prospective, Multicenter, Observational, Post-Authorization Study To Evaluate The Long-Term Safety Profile Of Lemtrada Treatment In Patients With Relapsing Forms Of Multiple Sclerosis.

Novartis COMB157G2399- An open-label, single-arm, multi-center extension study evaluating long-term safety, tolerability, and effectiveness of Ofatumumab in subjects with relapsing multiple sclerosis

Avanir 15-AVP-786-301-A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety, and Tolerability Of AVP-786 For The Treatment Of Agitation In Patient With Dementia Of The Alzheimer’s Type.

Luitpold 1VIT13037 – A double-blind, multi-center, randomized, placebo-controlled study to investigate the efficacy and safety of Injectafer (Ferric Carboxymaltose) in the treatment of Restless Legs Syndrome (RLS)

Bayer Healthcare/Xcenda 17942 – Impact of the BETACONNECT auto-injector on BETASERON therapy adherence and patient satisfaction

Amgen 20150133 Evidera A-16821 – A prospective observational study to evaluate tolerability and outcomes of prophylactic therapies in Migraines

BioDelivery BDSI BNX-401 – Prospective Evaluation of Treatment Satisfaction with Buprenorphine/Naloxone Buccal Film in Opioid Dependent Subjects

Biogen POP 105MS401 – Plegridy Observational Program to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS

Hoffman La-Roche VANILLA BP28420E – A multi-center, randomized, double-blind, 12-week parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of RO5285119 in individuals with Autism spectrum disorders (ASD)

Novartis EXPAND CBAF312A2304 – Evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis

Novartis PASSAGE FTY720D3403 – Safety Study in Patients with Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

PET STUDY DCA-2 – Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship between Scan Status and Cognitive Decline in Alzheimer’s Patients

UCB Bioscience SP0993 – Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Novartis PREFERMS CFTY720DUS09 –Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients with Relapsing Remitting Multiple Sclerosis

PET STUDY DCA-1 – Potential of Florbetapir F18 PET to Inform Clinical Diagnosis and Management of Alzheimer’s Patients with Progressive Cognitive Decline

Ipsen A-TL 52150-56 Anchor-DC – DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia

Genzyme OBS13434-A Prospective, Multicenter, Observational, Post-Authorization Study To Evaluate The Long-Term Safety Profile Of Lemtrada Treatment In Patients With Relapsing Forms Of Multiple Sclerosis.

Avanir 15-AVP-786-301-A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety, And Tolerability Of AVP-786 For The Treatment Of Agitation In Patients With Dementia Of The Alzheimer’s Type.

Luitpold 1VIT13037 – A double-blind, multi-center, randomized, placebo-controlled study to investigate the efficacy and safety of Injectafer (Ferric Carboxymaltose) in the treatment of Restless Legs Syndrome (RLS)

Bayer Healthcare/Xcenda 17942 – Impact of the BETACONNECT auto-injector on BETASERON therapy adherence and patient satisfaction

Amgen 20150133 Evidera A-16821 – A prospective observational study to evaluate tolerability and outcomes of prophylactic therapies in Migraines

BioDelivery BDSI BNX-401 – Prospective Evaluation of Treatment Satisfaction with Buprenorphine/Naloxone Buccal Film in Opioid-Dependent Subjects

Biogen POP 105MS401 – Plegridy Observational Program to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS

Hoffman La-Roche VANILLA BP28420E – A multi-center, randomized, double-blind, 12-week parallel-group, placebo-controlled proof of concept study to investigate the efficacy and safety of RO5285119 in individuals with Autism spectrum disorders (ASD)

Novartis EXPAND CBAF312A2304 – Evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis

2013 Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (PASSAGE)

2013 Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

2013 Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older (SP0993)

2013 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. (PREFERMS)

2013 Huntington’s Disease lecture and discussion, Huntington’s Disease Society of America, Boca Raton, FL

2013 Neurologic Emergencies, Grand Rounds, Broward Health Coral Springs, Coral Springs, FL

2012 Potential of Florbetapir F18 PET to Inform Clinical Diagnosis and Management of Patients with Progressive Cognitive Decline

2012 DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD) LECTURE ACTIVITIES

2012 Neurologic Emergencies and Epilepsy lectures, Saint George’s University, Grenada

2008 Neurologic Changes with Aging, West Boca Medical Center, Boca Raton, FL

2008 Stroke, West Boca Medical Center, Boca Raton, FL

2003 Aseptic Meningitis after use of Rofecoxib, a clinical vignette for American College of Physicians, Southeast Regional Meeting, New Orleans, LA

2002 Guillain-Barré Syndrome and Myasthenia Gravis, Neurology lecture series, Tulane Health Sciences Center, New Orleans, LA

2001 Stroke, Neurology Grand Rounds, Veterans Administration, New Orleans, LA